ArticleThe Journal of antimicrobial chemotherapy2024
Retrospective evaluation of rapid genotypic ID and phenotypic AST systems on positive blood culture turnaround time and simulated potential impacts on bloodstream infection management.
Article in The Journal of antimicrobial chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Evaluation of Q-linea ASTar rapid phenotypic antimicrobial susceptibility testing and potential impact in patients with gram-negative bloodstream infections.Microbiology spectrum · 2026Article
- Rapid Microbiological Diagnostics for Sepsis: Narrative Review of Current and Prospective Approaches.Critical care explorations · 2026Review
- When Hours Matter: A 24/7 Laboratory and Fast-Track Diagnostic Pathway for Blood Cultures in Critical Patients.Antibiotics (Basel, Switzerland) · 2026Article
- Performance of direct-from-blood culture bottle rapid phenotypic antimicrobial susceptibility testing for Gram-negative bacteremia at a children's hospital.JAC-antimicrobial resistance · 2025Article
- Improving time-to-result: head-to-head comparison of three rapid AST systems for Gram-negative bacteremia, including the newly developed VITEK REVEAL.Journal of clinical microbiology · 2025Article
- Diagnostic stewardship in sepsis: minding the gap from the microbiology lab to ward.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- Advancements and Future Perspectives of Microfluidic Technology in Pediatric Healthcare.Smart medicine · 2025Review
- Integrating Lean Six Sigma into Microbiology Laboratories: Insights from a Literature Review.Healthcare (Basel, Switzerland) · 2025Review
- Verification of the Vitek Reveal System for Direct Antimicrobial Susceptibility Testing in Gram-Negative Positive Blood Cultures.Antibiotics (Basel, Switzerland) · 2024Article
- Evaluating the impact of rapid antimicrobial susceptibility testing for bloodstream infections: a review of actionability, antibiotic use and patient outcome metrics.The Journal of antimicrobial chemotherapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBloodstream infections are linked to heightened morbidity and mortality rates. The consequences of delayed antibiotic treatment can be detrimental. Effective management of bacteraemia hinges on rapid antimicrobial susceptibility testing.
objectivesThis retrospective study examined the influence of the VITEK® REVEAL™ Rapid AST system on positive blood culture (PBC) management in a French tertiary hospital. MATERIALS AND
methodsBetween November 2021 and March 2022, 79 Gram-negative monomicrobial PBC cases underwent testing with both VITEK®REVEAL™ and VITEK®2 systems.
resultsThe study found that VITEK®REVEAL™ yielded better results than the standard of care, significantly shortening the time to result (7.0 h compared to 9.6 h) as well as the turnaround time (15 h compared to 31.1 h) when applied for all isolates.
conclusionsThis study implies that the use of VITEK®REVEAL™ enables swift adaptations of antibiotic treatment strategies. By considerably minimizing the turnaround time, healthcare professionals can promptly make necessary adjustments to therapeutic regimens. Notably, these findings underscore the potential of VITEK®REVEAL™ in expediting appropriate antibiotic interventions, even in less ideal conditions. Further studies in varied laboratory contexts are required to validate these encouraging outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.